Haleon to invest $54 mln in US R&D centre to ... invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovations.

As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding ...

Sensodyne toothpaste maker Haleon hailed an ‘important milestone’ as an independent company after US pharma giant Pfizer sold its remaining stake in the business. Shares in the consumer health ...

Haleon PLC HLN shares slid 1.91% to £3.86 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.10% to 8,638.01. Haleon PLC ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Pfizer Inc. (PFE) announced the sales of around 618 million ordinary shares in Haleon plc (HLN) at a price of 385 pence or about $5.01 per Ordinary Share for gross proceeds of ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and ...

In a report released on March 20, Karel Zoete from Kepler Capital maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of p440.00. The company’s shares closed ...